Chronic myeloid leukemia (CML) is usually treated with either alpha-interferon or hydrea. Median survival is 6 years. Eventually, in most CML patients, the disease evolves to blast phase with clinical and morphologic characteristics of an acute leukemia. This phase is commonly associated with systemic symptoms and the appearance of new cytogenetic abnormalities. Therapy for this phase is of limited value, resulting in a mean survival of 4 months. We describe four consecutive patients seen at our clinic with advanced stage CML (three blast, one accelerated phase) who were treated with interleukin-2 (Proleukin). The mean survival in these patients was 22 months (range 9-35 months) and two are still alive 25 and 35 months after the start of therapy. One patient had a complete cytogenetic response and another a partial response. Toxicity was minimal and no patient had to discontinue therapy because of it.
Introduction
Chronic myelogenous leukemia (CML) remains an incurable disease for a great majority of patients. Allogeneic bone marrow transplant (allo-BMT) from matched donors remains the only curative procedure and is associated with long-term disease-free survival of approximately 60% for patients in chronic phase. 1, 2 Unfortunately, most patients with CML are ineligible for allo-BMT either because of risk factors or lack of compatible donors. The administration of alpha interferon (IFN ␣) has improved the median survival to 6 years vs 4. years for patients treated with chemotherapy alone. 3 Although IFN ␣ has become the treatment of choice for patients ineligible for allo-BMT, few if any, patients are cured by this therapy.
The prognosis for patients with accelerated or blast phase CML remains bleak. Regardless of therapy, the expected mean survival is 3-4 months for patients in blast phase. 4 Allo-BMT remains an option for these patients with a suitable match, but results are still poor with disease-free survival of only 20% at 1 year. 5 CML appears to be unique among the hematological malignancies in that a potent graft-versus-leukemia (GVL) response occurs in allogeneic transplant recipients. The exact mechanism responsible for GVL remains unknown. Lymphocytes appear to play an important role as T cell-depleted and syngeneic marrow transplant recipients experience higher relapse rates than those who receive unmanipulated marrow or antigen mismatched transplants. 6, 7 Moreover, buffy coat infusions of donor T cells result in a durable remission of 70% for patients who relapse after allo-BMT without additional chemotherapy. 8 We treated four patients with advanced CML 
Patient 2
KW, a 28-year-old woman diagnosed with CML in 1992, was initially treated with hydrea and intermittent IFN ␣. In January 1996, she progressed to a myeloid blast crisis (characterized as megakaryoblastic) and was treated with high-dose Ara-C and daunorubicin (as previously described in patient 1). She returned to chronic phase CML. Three months later, her white blood cell count increased to 56 000/l (3% blasts) while maintaining a hematocrit of 29% and a platelet count of 184 000/l. She was treated with continous infusion IL-2 (IL-2 6 × 10 6 units/daily × 5 days) with an immediate decrease of the white blood cell count to 7000/l and the disappearance of blasts in her peripheral blood. There was also a dramatic decrease in spleen size. She was then started on daily subcutaneous maintenance doses of IL-2 (IL-2 1 × 10 6 units/m 2 ) and IFN ␣ (5 × 10 6 units). She did not achieve a complete remission, but reverted to chronic phase, with blood counts at 6 months after initiation of therapy showing a hematocrit of 27%, platelet count of 149 000/l, and a white blood cell count of 7600/l with 10% myelocytes and no circulating blasts. She remained on therapy for 12 months, when blast phase again supervened, and she died shortly thereafter. The only complication of therapy was the development of indurated, pruritic areas of skin at the injection sites, which resolved over 4-5 days without any therapy.
Patient 3
MP, a 54-year-old male diagnosed with CML in 1988, was treated with hydrea until 1991, when IFN ␣ was added. Hydrea was tapered off over 3 months while IFN ␣ was continued until July 1994. At that time, he progressed to an accelerated phase characterized by fevers, splenomegaly, thrombocytopenia, and fatigue. In February 1995, his white blood cell count was 57 000/l with a hematocrit of 30%, and a platelet count of 28 000/l. A bone marrow examination showed Ͻ5% blasts but there were new chromosomal abnormalities. The patient was considered to be in accelerated phase rather than in blast crisis, therefore cytoreductive chemotherapy was not administered. At that time, he was treated with continuous infusion IL-2 (IL-2 6 × 10 6 units/day × 5 days), followed by daily maintenace subcutaneous IL-2 (1 × 10 6 units/m 2 ). Subcutaneous IFN ␣ was also continued at a dose of 3 × 10 6 units daily. Splenomegaly, thrombocytopenia, and subjective symptoms resolved. His white blood cell count ranged from 10-15 000/l (approximately 5% myeloblasts and 5% promyelocytes in the circulation) with a platelet count of 150-180 000/l, and a stable hematocrit at 35%. A partial cytogenetic response (10% normal metaphases in the bone marrow) occurred 12 months after beginning IL-2. After 35 months of therapy, he entered a blast phase and is currently being treated with low-dose cytarabine to control his rising blast count.
Patient 4
BS, a 36-year-old woman diagnosed with CML in 1994, was initially treated with hydrea and INF ␣. She never achieved a complete hematologic remission but remained in chronic stable phase until January 1996 when she developed bone pain. A bone marrow examination at that time showed 16% blasts and 15% basophils. She continued on modified doses of hydrea and IFN ␣ until January 1997 when she developed progressive anemia (hematocrit falling to 20%, white blood cell count 1300/l, and platelet count 550 000/l), associated with fever, nights sweats, abdominal and bone pain, and mild splenomegaly. A bone marrow aspirate confirmed blast crisis. There was marked reticulum fibrosis and megakaryocytic hyperplasia. Flow cytometry was consistent with megakaryoblastic differentiation (CD42 positive). She received highdose cytarabine (1.5 g/m 2 every 12 h × 12 doses). Follow-up bone marrow biopsy performed 3 weeks later revealed a markedly hypocellular bone marrow with occasional focal clusters of blast cells. After recovery from chemotherapy, her peripheral white blood cell count rose to 69 000/l with 2% blasts. She was then started on hydrea and subcutaneous IL-2 (IL-2 6 × 10 6 units/day for 5 days decreasing to 1 × 10 6 units/m 2 /daily). Her hematocrit rose to 37% and her white blood cell count fell, stabilizing in the 3-4000/l range, without any circulating blasts. Her platelet count rose to a range of 500-900 000/l with resolution of systemic symptoms and splenomegaly. Bone marrow biopsy and aspirate done in April and July 1997 showed a minimal number of blasts (8%). She received a haplotype mismatched allotransplant on 17 August 1997, but died 1 month later from complications associated with the transplant. The only complication of IL-2 therapy was the development of indurated, pruritic areas of skin at the injection sites, which resolved over 4-5 days without any therapy. Table 1 provides a summary of the salient features of these patients.
Discussion
Interleukin-2 has been used in the treatment of acute myeloid leukemia with occasional success 9 but there is very little experience with its use in the blast phase of CML. The four patients described here had few adverse side-effects from the daily IL-2 treatment despite prolonged therapy. Two patients remain alive after more than 2 years of treatment. One patient is in complete cytogenetic remission and the other in partial remission. The other two patients had hematologic responses, lasting 8 and 12 months. The only recurrent problem was erythema and tender nodules at the injection site. These readily resolved despite continuing injections in other cutaneous sites. No patient experienced capillary leak syndrome, recurrent fever, or cytopenias that required dose modification.
Despite previous failure with IFN ␣ it was continued in three of these patients as some patients with previously IFN ␣-resistant disease become responsive to its effects after allo-BMT. 10 Three of the four patients received high-dose cytarabine for cytoreduction, which may have had an effect in modifying IFN ␣ sensitivity. In addition, stimulation of T cells by IL-2 may have also contributed to producing a synergistic effect with interferon ␣ as the latter up-regulates HLA class II antigen expression facilitating an immune response.
The mechanism by which T cells mediate antitumor effects in CML is poorly defined. The presence of a unique tumor antigen in CML may allow for this directed response. Translocation of the human abl proto-oncogene from chromosome 9 to a specific breakpoint cluster region (bcr) on chromosome 22 is the hallmark of CML. The resulting fusion gene encodes for a 210-kDa protein with abnormal tyrosine kinase activity. Immunizing mice with this chimeric protein elicits a specific CD4 T lymphocyte response, which is confined to the bcrabl amino acid sequence (fusion protein) and not to peptide sequences of bcr or abl alone. 11 That the bcr-abl-derived peptide sequence can elicit a peptide-specific cytotoxic T cell response was demonstrated using peripheral blood mononuclear cells from HLA-matched healthy human donors. 12 Moreover, reactive bone marrow mononuclear cells derived from patients with CML greatly expand when exposed to IL-2 and autologous tumor. The proliferating T cells display substantial cytotoxicity in assays using 51 Cr-labeled autologous CML cells as targets, 13 whereas nonspecific natural killer (NK) and lymphocyte activated killer (LAK) cell activity did not increase. The bcr-abl fusion protein may well be the target for the potent T cell-mediated attack in CML.
IL-2, a lymphokine normally produced by T lymphocytes, supports the proliferation and activation of NK cells and T cells. IL-2 also induces the release of cytokines from T cells and NK cells such as tumor necrosis factor, granulocytemacrophage colony-stimulating factors (GM-CSF), and gamma interferon. The effects of T cell proliferation on chemotherapy-resistant clonogenic CML cells may be enhanced when a state of minimal residual disease exists.
IL-2 may also have other useful direct effects on the bcr/abl fusion protein. IL-2 inhibits the transcription of the bcr/abl transgene in CML cell lines. IL-2 reduced bcr/abl mRNA 17 administered a short course of high-dose IL-2 to 11 patients with interferon-resistant chronic phase CML resulting in a cytogenetic response in four patients. Mazumder and collegues 18 exposed CML cells, harvested for autografts, to IL-2 in a 2 week culture system, resulting in complete purging of CML clones as determined by cytogenetic analysis.
All four patients described here responded to therapy and were consecutive patients who presented at our institution. The degree of cytoreduction prior to IL-2 therapy in three patients and the co-administration of interferon make uncertain the precise contribution of IL-2 to the outcome in these patients. Nevertheless, the duration of response and overall survival of these patients compares favorably to the usually brief survivorship reported for combination chemotherapy in blast phase CML. These results are sufficiently encouraging to now form the basis for a larger phase II trial in the Eastern Cooperative Oncology Group.
